It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Subscribe To Our Newsletter & Stay Updated
